Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO® (Delayed-release Budesonide Capsules) Treatment in Adult Patients With Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO® 16 mg Once Daily Treatment in Real-world Clinical Practice

NCT06712407 is registered in ClinicalTrials.gov with Calliditas Therapeutics AB as lead sponsor.

NCT NCT06712407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO® (Delayed-release Budesonide Capsules) Treatment in Adult Patients With Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO® 16 mg Once Daily Treatment in Real-world Clinical Practice
Lead sponsor
Calliditas Therapeutics AB
Phase
Phase 4
Overall status
Active, not recruiting
Start date
December 17, 2024
Completion date
February 29, 2028
Enrollment
60 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy